Multiple abnormalities of the p16(INK4a)-pRb regulatory pathway in cultured melanoma cells

Melanoma Research

Volumn 9, Issue 1, 1999, Pages 10-19

  Rizos, H ^a   Darmanian, A P ^a   Indsto, J O ^a   Shannon, J A ^a   Kefford, R F ^a   Mann, G J ^a  

^a UNIVERSITY OF SYDNEY   (Australia)

Author keywords

CDK4 gene; CDKN2A gene; Cell cycle; Melanoma cells; Retinoblastoma protein

Indexed keywords

PROTEIN P16; RETINOBLASTOMA PROTEIN; CYCLIN DEPENDENT KINASE; PROTEIN P16INK4A;

ARTICLE; CANCER CELL CULTURE; CANCER GENETICS; CONTROLLED STUDY; GENE DELETION; GENE MUTATION; GENE OVEREXPRESSION; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; MELANOMA; PRIORITY JOURNAL; TUMOR GROWTH; CELL CULTURE; CELL CYCLE; CELL DIVISION; GENE EXPRESSION REGULATION; GENETICS; IMMUNOBLOTTING; METABOLISM; NORTHERN BLOTTING; NUCLEOTIDE SEQUENCE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

BLOTTING, NORTHERN; CELL CYCLE; CELL DIVISION; CYCLIN-DEPENDENT KINASE INHIBITOR P16; CYCLIN-DEPENDENT KINASES; DNA MUTATIONAL ANALYSIS; GENE EXPRESSION REGULATION; HUMANS; IMMUNOBLOTTING; MELANOMA; RETINOBLASTOMA PROTEIN; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TUMOR CELLS, CULTURED;

EID: 0032589240     PISSN: 09608931     EISSN: None     Source Type: Journal    
DOI: 10.1097/00008390-199902000-00003     Document Type: Article

References (65)

1. 1. Sherr CJ. Cancer cell cycles. Science 1996; 274: 1672-1677.
2. INK4B is a potential effector of TGFβ induced cell cycle arrest. Nature 1994; 371: 257-261.
3. 3. Serrano M, Hannon GJ, Beach D. A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4. Nature 1993; 366: 704-707.
4. 4. Hirai H, Roussel MF, Kato JY, Ashmun RA, Sherr CJ. Novel INK4 proteins, p19 and p18, are specific inhibitors of the cyclin D-dependent kinases CDK4 and CDK6. Mol Cell Biol 1995; 15: 2672-2681.
5. 5. Schmidt EE, Ichimura K, Reifenberger G, Collins VP. CDKN2 (p16/MTS1) gene deletion or CDK4 amplification occurs in the majority of glioblastomas. Cancer Res 1994; 54: 6321-6324.
6. INK4A inactivation in non-small cell lung cancer cell lines. Cancer Res 1995; 55: 6200-6209.
7. 7. Maesawa C, Tamura G, Nishizuka S, Ogasawara S, Ishida K, Terashima M, Sakata K, Sato N, Saito K, Satodate R. Inactivation of the CDKN2 gene by homozygous deletion and de novo methylation is associated with advanced stage esophageal squamous cell carcinoma. Cancer Res 1996; 56: 3875-3878.
8. 8. Costello JF, Berger MS, Huang HJS, Cavenee WK. Silencing of p16/CDKN2 expression in human gliomas by methylation and chromatin condensation. Cancer Res 1996; 56: 2405-2410.
9. 9. Cheng JQ, Jhanwar SC, Klein WM, Bell DW, Lee WC, Altomare DA, Nobori T, Olopade OI, Buckler AJ, Testa JR. p16 alterations and deletion mapping of 9p21-p22 in malignant mesothelioma. Cancer Res 1994; 54: 5547-5551.
10. 10. Caldas C, Hahn SA, da Costa LT, Redston MS, Schutte M, Seymour AB, Weinstein CL, Hruban RH, Yeo CJ, Kern SE. Frequent somatic mutations and homozygous deletions of the p16 (MTS1) gene in pancreatic adenocarcinoma. Nature Genet 1994; 8: 27-32.
11. 11. Quesnel B, Preudhomme C, Philippe N, Vanrumbeke M, Dervite I, Lai JL, Bauters F, Wattel E, Fenaux P. p16 gene homozygous deletions in acute lymphoblastic leukemia. Blood 1995; 85: 657-663.
12. 1 regulation in human head and neck cancer. Cancer Res 1995; 55: 949-956.
13. 13. Igaki H, Sasaki H, Kishi T, Sakamoto H, Tachimori Y, Kato H, Watanabe H, Sugimura T, Terada M. Highly frequent homozygous deletion of the p16 gene in esophageal cancer cell lines. Biochem Biophys Res Commun 1994; 203: 1090-1095.
14. INK4B. Cancer Res 1996; 56: 722-727.
15. 15. Lohman DR, Brandt B, Höpping W, Passarge E, Horsthemke B. The spectrum of RB1 germ-line mutations in hereditary retinoblastoma. Am J Hum Genet 1996; 58: 940-949.
16. 16. Horowitz JM, Park SH, Bogenmann E, Cheng JC, Yandell DW, Kaye FJ, Minna JD, Dryja TP, Weinberg RA. Frequent inactivation of the retinoblastoma antioncogene is restricted to a subset of human tumour cells. Proc Natl Acad Sci USA 1990; 87: 2775-2779.
17. 17. He J, Allen JR, Collins VP, Allalunis-Turner MJ, Godbout R, Day RS III, James CD. CDK4 amplification is an alternative mechanism to p16 gene homozygous deletion in glioma cell lines. Cancer Res 1994; 54: 5804-5807.
18. (INK4b/MTS1) p18 and p19 in human cancer cell lines. Int J Cancer 1996; 68: 605-611.
19. INK4d, in tumor-derived cell lines and primary tumors. Oncogene 1996; 13: 2033-2038.
20. 20. Lapointe J, Lachance Y, Labrie Y, Labrie C. A p18 mutant defective in CDK6 binding in human breast cancer cells. Cancer Res 1996; 56: 4586-4589.
21. 21. Ohta M, Nagai H, Shimizu M, Rasio D, Berd D, Mastrangelo M, Singh AD, Shields JA, Shields CL, Croce CM, Huebner K. Rarity of somatic and germline mutations of the cyclin-dependent kinase 4 inhibitor gene, CDK41, in melanoma. Cancer Res 1994; 54: 5269-5272.
22. 22. Kamb A, Shattuck-Eidens D, Eeles R, Liu Q, Gruis NA, Ding W, Hussey C, Tran T, Miki Y, Weaver-Feldhaus J, McClure M, Aitken JF, Anderson DE, Bergman W, Frants R, Goldgar DE, Green A, MacLennan R, Martin NG, Meyer LJ, Youl P, Zone JJ, Skolnick MH, Cannon-Albright LA. Analysis of the p16 gene (CDKN2) as a candidate for the chromosome 9p melanoma susceptibility locus. Nature Genet 1994; 8: 23-26.
23. 23. Hussussian CJ, Struewing JP, Goldstein AM, Higgins PA, Ally DS, Sheahan MD, Clark W Jr, Tucker MA, Dracopoli NC. Germline p16 mutations in familial melanoma. Nature Genet 1994; 8: 15-21.
24. 24. Borg A, Johansson U, Johannsson O, Håkansson S, Westerdahl J, Mǎsbäck A, Olsson H, Ingvar C. Novel germline p16 mutation in familial malignant melanoma in southern Sweden. Cancer Res 1996; 56: 2497-2500.
25. 25. Gruis NA, Van der Velden PA, Sandkuijl LA, Prins DE, Weaver-Feldhaus J, Kamb A, Bergman W, Frants RR. Homozygotes for CDKN2 (p16) germline mutation in Dutch familial melanoma kindreds. Nature Genet 1995; 10: 351-353.
26. 26. Holland EA, Beaton SC, Becker TM, Grulet OMC, Peters BA, Rizos H, Kefford RF, Mann GJ. Analysis of the p16 gene, CDKN2, in 17 Australian melanoma kindreds. Oncogene 1995; 11: 2289-2294.
27. INK4A mutation and protein dysfunction in a family with inherited melanoma. Oncogene 1995; 11: 405-412.
28. INK4 gene in Australian melanoma kindreds. Hum Mol Genet 1995; 4: 1845-1852.
29. INK4a binding domain of CDK4 in familial melanoma. Nature Genet 1996; 12: 97-99.
30. 30. Reymond A, Brent R. p16 proteins from melanomaprone families are deficient in binding to Cdk4. Oncogene 1995; 11: 1173-1178.
31. 31. Koh J, Enders GH, Dynlacht BD, Harlow E. Tumour-derived p16 alleles encoding proteins defective in cell-cycle inhibition. Nature 1995; 375: 506-510.
32. CDKN2 associated with familial melanoma. Mol Cell Biol 1996; 16: 3844-3852.
33. INK4 function. Nature Genet 1995, 10: 114-116.
34. INK4b genes, as well as neighboring 9p21 markers, in sporadic melanoma. Cancer Res 1996; 56: 5023-5032.
35. 35. Mœlandsmo GM, Flørenes VA, Hovig E, Øyjord T, Engerbraaten O, Holm R, Børresen A-L, Fodstad Ø. Involvement of the pRh/pI6/cdk4/cyclinDI pathway in the tumorigenesis of sporadic malignant melanoma. Br J Cancer 1996; 73: 909-916.
36. 36. Piccinin S, Doglioni C, Maestro R, Vukosavljevic T, Gasparotto D, D'Orazi C, Boiocchi M. p16/CDKN2 and CDK4 gene mutations in sporadic melanoma development and progression. Int J Cancer 1997; 74: 26-30.
37. 37. Bartkova J, Lukas J, Guldberg P, Alsner J, Kirkin AF, Zeuthen J, Bartek J. The p16-cyclin D/CDK4-pRb pathway as a functional unit frequently altered in melanoma pathogenesis. Cancer Res 1996; 56: 5475-5483.
38. 38. Castellano M, Pollock PM, Walters MK, Sparrow LE, Down LM, Gabrielli BG, Parsons PG, Hayward NK. CDKN2A/p16 is inactivated in most melanoma cell lines. Cancer Res 1997; 57: 4868-4875.
39. 39. Liu Q, Neuhausen S, McClure M, Frye C, Weaver-Feldhaus J, Gruis NA, Eddington K, Allalunis-Turner MJ, Skolnick MH, Fujimura FK, Kamb A. CDKN2 (MTS1) tumor suppressor gene mutations in human tumor cell lines. Oncogene 1995; 10: 1061-1067.
40. 40. Quelle DE, Zindy F, Ashmun RA, Sherr CJ. Alternative reading frames of the INK4a tumor suppressor gene encode two unrelated proteins capable of inducing cell cycle arrest. Cell 1995; 83: 993-1000.
41. 41. Weaver-Feldhaus J, Gruis NA, Neuhausen S, Le Paslier D, Stockert E, Skolnick MH, Kamb A. Localization of a putative tumor suppressor gene by using homozygous deletions in melanomas. Proc Natl Acad Sci USA 1994; 91: 7563-7567.
42. 42. Kamb A, Gruis NA, Weaver-Feldhaus J, Liu Q, Harshman K, Tavtigian SV, Stockert E, Day RS III, Johnson BE, Skolnick MH. A cell cycle regulator potentially involved in genesis of many tumor types. Science 1994; 264: 436-440.
43. CDKN2 expression and its implications for cell immortalization and senescence. Mol Cell Biol 1996; 16: 859-867.
44. 44. Shiohara M, El-Deiry WS, Wada M, Nakamaki T, Takeuchi T, Yang R, Chen D-L, Vogelstein B, Koeffler HP. Absence of WAF1 mutations in a variety of human malignancies. Blood 1994; 84: 3781-3784.
45. 45. El-deiry WS, Tokino T, Velculescu VE, Levy DB, Parsons R, Trent JM, Lin D, Mercer WE, Kinzler KW, Vogelstein B. WAF1, a potential mediator of p53 tumor suppression. Cell 1993; 75: 817-825.
46. 46. Fountain JW, Bale SJ, Housman DE, Dracopoli NC. Genetics of melanoma. Cancer Surv 1990; 9: 645-671.
47. INK4a and p16β transcripts in B-lymphoblastoid cells from members of hereditary melanoma families without CDKN2A exon mutations. Oncogens 1997; 15: 515-523.
48. 18. Indsto JO, Holland EA, Kefford RF, Mann GJ. 10q deletions in metastatic cutaneous melanoma. Cancer Genet Cytogenet 1998; 100: 68-71.
49. 49. Stone S, Dayananth P, Jiang P, Weaver-Feldhaus JM, Tavtigian SV, Cannon-Albright L, Kamb A. Genomic structure, expression and mutational analysis of the P15 (MTS2) gene. Oncogene 1995; 11: 987-991.
50. INK4 gene) during tumour progression in a sporadic melanoma patient. Cancer Res 1995; 55: 5531-5535.
51. INK4a-insensitive CDK4 mutant targeted by cytolytic T lymphocytes in a human melanoma. Science 1995; 269: 1281-1284.
52. INK4a and CDK4 genes in 48 melanoma families. Melanoma Res 1997; 7(suppl 1): S132.
53. 53. Pollock PM, Yu F, Qiu L, Parsons PG, Hayward NK. Evidence for u.v. induction of CDKN2 mutations in melanoma cell lines. Oncogene 1995; 11: 663-668.
54. INK4B/MTS2 in human leukemias and lymphomas. Cancer Res 1995; 55: 1436-1440.
55. 55. Herman JG, Merlo A, Mao L, Lapidus RG, Issa J-PJ, Davidson NE, Sidransky D, Baylin SB. Inactivation of the CDKN2/p16/MTS1 gene is frequently associated with aberrant DNA methylation in all common human cancers. Cancer Res 1995; 55: 4525-4530.
56. 56. Ng MH, Chung YF, Lo KW, Wickham NW, Lee JC, Huang DP. Frequent hypermethylation of p16 and p15 genes in multiple myeloma. Blood 1997; 89: 2500-2506.
57. 57. Martinez-Delgado B, Robledo M, Arranz E, Osorio A, Garcia MJ, Echezarreta G, Rivas C, Benitez J. Hypermethylation of p15/ink4b/MTS2 gene is differentially implicated among non-Hodgkin's lymphomas. Leukemia 1998; 12: 937-941.
58. INK4 in human cancer. Proc Natl Acad Sci USA 1994; 91: 11045-11049.
59. INK4A in archival human solid tumors: correlation with retinoblastoma protein expression. Cancer Res 1995; 55: 6006-6011.
60. 60. Platz A, Ringborg U, Lagerlöf B, Lundqvist E, Sevigny P, Inganäs M. Mutational analysis of the CDKN2 gene in metastases from patients with cutaneous malignant melanoma. Br J Cancer 1996; 73: 344-348.
61. INK4a) gene in microdissected sporadic primary melanomas. Int J Cancer 1998; 75: 193-198.
62. INK4 proteins in cutaneous malignant melanoma. Br J Dermatol 1996; 134: 269-275.
63. INK4a expression is frequently decreased and associated with 9p21 loss of heterozygosity in sporadic melanoma. J Cutan Pathol 1998; 25: 291-296.
64. 64. Gonzalgo ML, Bender CM, You EH, Glendening MJ, Flores JF, Walker GJ, Hayward NK, Jones PA, Fountain JW. Low frequency of p16/CDKN2A methylation in sporadic melanoma: comparative approaches for methylation analysis of primary tumors. Cancer Res 1997; 57: 5336-5347.
65. 65. Guldberg P, Kirkin AF, Grønbæk K, Streten PT, Ahrenkiel V, Zeuthen J. Complete scanning of the CDK4 gene by denaturing gradient gel electrophoresis: a novel missense mutation but low overall frequency of mutations in sporadic metastatic malignant melanoma. Int J Cancer 1997; 72: 780-783.